english.prescrire.org > Prescrire International > N°145 - January 2014

n°145

January 2014

Issue Contents
Editorial

Free  Classics

p.4
A cool head is needed when dealing with industry hype and fads

New Products


Artenimol + piperaquine (New Drug)

p.5-8
Very slow piperaquine elimination: cardiovascular risks and interactions

Regorafenib (New Drug)

p.8-11
Metastatic colorectal cancer in treatment failure: may prolong survival by a few weeks

Everolimus after liver transplantation (New Indication)

p.12
Choose better-documented immunosuppressant combinations

INN common stem: -imod

p.12

Everolimus: a drug with two faces

p.12

Fingolimod (New Warnings)

p.13
Check cardiovascular status again on treatment resumption

Adverse Effects


Insulin use: preventable errors

p.14-17
Involving patients in treatment is essential

Free  Bowel cleansers: serious adverse effects

p.18
Gastritis, hyponatraemia

Free  Fentanyl patches: deaths in children

p.18
Safe disposal of used patches is a must

Free  Zolpidem: next-morning residual effects

p.18
No safer than benzodiazepines

Reviews


Screening for lung cancer

p.19-23
Too many uncertainties, even for smokers

Post-exposure tuberculosis in children under 5 years old

p.23
A large-scale study confirms the high risk

Outlook


An approach to preventing adverse drug effects during pregnancy

p.24-26
Read up and think hard before prescribing

The power of a study: detecting teratogenicity

p.25

Free  Conflicts of interest in France: feeble reform

p.27
French policy-makers have overlooked patients' interest

Masthead


Free  Masthead

p.2

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe